Patents by Inventor William Dole

William Dole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 10870698
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 22, 2020
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190040128
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 7, 2019
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9988455
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9982046
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 29, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170260272
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: December 23, 2016
    Publication date: September 14, 2017
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170152313
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 1, 2017
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9562101
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: February 7, 2017
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9512222
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20150004168
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: January 1, 2015
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20140377281
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: December 25, 2014
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Jennifer BROGDON, William DOLE, John TRAUGER, Yuting TANG, Julia NEUGEBAUER, Annika SCHMID
  • Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis
    Publication number: 20080269247
    Abstract: The present invention relates to piperazine derivatives of formulae Ia, Ib, Ic and Id and their use to treat myocarditis. where R1a, R1b, R2, R3, R4, R5, R6, R9, R10 and Y are as defined herein.
    Type: Application
    Filed: August 6, 2007
    Publication date: October 30, 2008
    Inventors: Hideki Futamatsu, Mitsuaki Isobe, Noritaka Koga, Jun-ichi Suzuki, William Dole
  • Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI
    Publication number: 20060234986
    Abstract: This invention relates to TAFI inhibitors and their use to enhance myocardial reperfusion and facilitate percutaneous coronary intervention (PCI) in the treatment of acute ST elevation myocardial infarction (STEMI).
    Type: Application
    Filed: April 11, 2006
    Publication date: October 19, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Brad Buckman, William Dole, Kohichi Kawai, Michael Morser, Mariko Nagashima, Ronald Vergona, Yi-Xin Wang
  • Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
    Publication number: 20050043318
    Abstract: The present invention relates to piperazine derivatives of formulae Ia, Ib, Ic and Id and their use to treat myocarditis. where R1a, R1b, R2, R3, R4, R5, R6, R9, R10 and Y are as defined herein.
    Type: Application
    Filed: August 20, 2004
    Publication date: February 24, 2005
    Applicants: Schering Aktiegesellschaft, Tokyo Medical and Dental University
    Inventors: Hideki Futamatsu, Mitsuaki Isobe, Noritaka Koga, Jun-ichi Suzuki, William Dole
  • Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
    Publication number: 20050014783
    Abstract: The present invention is directed to a method for preventing or decreasing the incidence of or treating aneurysm or cardiac hypertrophy, comprising administering an effective amount of a rho-kinase inhibitor, such as fasudil, to a subject in need thereof.
    Type: Application
    Filed: May 28, 2004
    Publication date: January 20, 2005
    Applicant: Schering Aktiengesellschaft
    Inventors: William Dole, David Light, Baby Martin-McNulty, Sabine Schirm, Yi-Xin Wang
  • Test interface for coaxial cable
    Patent number: 6428356
    Abstract: A test interface between cable testing apparatus and a coaxial cable for testing the coaxial cable over a frequency range of interest. The test interface comprises a coupler having a cable lead-in opening at a first end and a threaded, connector contact portion near a second end, an insert that abuts an interior shoulder of the coupler proximate the connector contact portion, the insert having a wall portion that projects outwardly toward the second end of the coupler, and a pin constructed and arranged to abut a center conductor of the coaxial cable, the pin substantially centrally positioned within the outwardly projecting wall portion of the insert. The coupler, insert, and pin mechanically and electrically interconnect with a mating electrical connector to provide a reusable electrical connection between the cable testing apparatus and the coaxial cable.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: August 6, 2002
    Assignee: Belden Wire & Cable Company
    Inventor: Carl William Dole